ArticleClinical case reports2026
Seronegative Morvan Syndrome Presenting With Agrypnia Excitata and Peripheral Nerve Hyperexcitability: A Phenotype-Supported Diagnostic and Therapeutic Approach in a Resource-Limited Setting.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 63-year-old Palestinian man with seronegative Morvan syndrome presenting with the complete clinical triad: continuous neuromyotonia with visible myokymia, severe insomnia consistent with agrypnia excitata phenotype (2-3 h/night; Insomnia Severity Index [ISI] 24/28, validated Arabic version), tachycardia (118 bpm), profuse diaphoresis, and 13-kg weight loss. Electromyography (EMG) demonstrated characteristic myokymic (40-150 Hz) and neuromyotonic (> 150 Hz) discharges across 12 muscles without denervation. Brain MRI, CSF analysis, and comprehensive malignancy screening were unremarkable. Validated cell-based assays confirmed seronegativity for CASPR2 and LGI1 in both serum and CSF. A phenotype-supported diagnosis was pursued integrating the clinical triad, electrophysiological confirmation, and systematic exclusion of mimics. Combined immunotherapy (intravenous methylprednisolone, prednisone taper, azathioprine) and symptomatic treatment (carbamazepine, melatonin) resulted in marked clinical improvement at 6 months: Medical Research Council (MRC) sum score 48 → 58/60, creatine kinase (CK) 928 → 185 U/L, ISI 24 → 4, and sleep restored to 7-8 h/night, with no significant adverse effects. This case illustrates a phenotype-supported diagnostic approach applicable in resource-limited settings where first-line biological therapies are unavailable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.